Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies_ Devices, Technology, Imaging & Health IT
Epic Sciences

Organization & Developments: Epic Sciences

Parents

2014: Developing diagnostic tests that molecularly characterize circulating tumor cells (CTCs) in the blood to provide a way to detect cancer and to monitor and personalize cancer treatments.
2014: Epic Sciences Compiling Data on Ultra-Sensitive Cancer Diagnostic
2014: Under their agreement, LabCorp’s central lab in Belgium will pre-process blood samples from clinical trials throughout Europe and send prepared slides to Epic’s certified lab in La Jolla.
Company’s technology can be used as a “companion diagnostic” to categorize patients for particular cancer drugs
Describes its test as a “blood fluid biopsy” to detect and analyze circulating tumor cells in blood samples
Epic uses fluorescent antibodies that bind to cytokeratins, a key protein in circulating tumor cells that can be used to identify different types of carcinomas.
The basis of the company’s CTC platform has been exclusively licensed from Dr. Peter Kuhn’s laboratory at The Scripps Research Institute.
The contract will fund the further development of an assay to identify and characterize circulating tumor cells (CTCs) in lung cancer patients.